Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Details

ISSN :

15565068

Database :

OpenAIRE

Journal :

SSRN Electronic Journal

Accession number :

edsair.doi...........a1c7f06784ab2206eea3b022be631c2c

Full Text :

https://doi.org/10.2139/ssrn.4060778